Immunohistochemistry (IHC) - Market Insights, Competitive Landscape, and Market Forecast- 2030

The market is expected to advance at a respectable CAGR forecast till 2030 owing to the growing instances of infectious diseases and increasing product developmental activities worldwide.

The immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 3.98 billion by 2030. The immunohistochemistry (IHC) market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), increasing instances of cancer, rising product developmental activities by market key players, among others that are factors expected to escalate the overall immunohistochemistry (IHC) market during the forecast period from 2024 to 2030.

Immunohistochemistry (IHC) Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Immunohistochemistry is essential in HIV diagnostics by detecting viral antigens in tissue samples, such as the HIV-1 p24 protein, which helps assess viral load and tissue involvement.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these, 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. For hepatitis B, immunohistochemistry can identify surface antigens like HBsAg in liver biopsies, aiding in the assessment of liver pathology and the degree of inflammation or fibrosis. In hepatitis C, it is used to visualize core proteins and NS proteins, assisting in understanding viral load and the host response in liver tissues. Thereby growing burden of infectious diseases worldwide will create need for accurate and rapid diagnostics significantly drives the market for immunohistochemistry.

The Global Cancer Observatory (2024), estimated that the new instances of cancer globally would reach from 20 million to 24.1 million by the year 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases. For cancer amid rising global cases immunohistochemistry detects specific tumor markers in tissue samples, aiding classification and treatment decisions by assessing biomarkers like hormone receptors and PD-L1. This enhances personalized medicine and improves patient outcomes resulting into increased demand for immunohistochemistry.

Additionally, in July 2021, Agilent Technologies Inc.’s PD-L1 IHC 22C3 pharmDx assay was labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Therefore, the factors stated above collectively will drive the overall immunohistochemistry market growth.

However, specificity & sensitivity issues associated with immunohistochemistry, availability of alternative options in the market, and others may limit their end-user base, thus acting as key constraints limiting the growth of the immunohistochemistry market growth.

Immunohistochemistry (IHC) Market Segment Analysis:

Immunohistochemistry (IHC) Market by Product Type (Instruments, Reagents & Kits, and Services), Application (Diagnostic, Research, and Forensic), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the immunohistochemistry market, the reagents & kits category is expected to have a significant revenue share in the year 2023. This is due to various features and applications offered by these devices.

Immunohistochemistry kits and reagents are essential tools for detecting specific antigens in tissue sections, utilizing antigen-antibody binding to visualize protein expression. Key features of immunohistochemistry kits and reagents include optimized, ready-to-use primary and secondary antibodies, detection systems with chromogenic or fluorescent labels, and buffers that enhance staining quality.

Immunohistochemistry kits and reagents are widely used in pathology for cancer diagnostics, where they help identify tumor subtypes and prognostic markers such as HER2, ER, and PR in breast cancer. They are also applied in the detection of infectious agents, such as in tuberculosis and viral infections, and in the research of neurological diseases, allowing visualization of protein aggregates like amyloid plaques in Alzheimer’s disease.

Moreover, introduction of new products in this category will further drive the market for same. For example in March 2023, Aptamer Group launched a new reagent solution, Optimer-Fc for use in automated immunohistochemistry workflows.

Therefore, the widespread uses and various advantages of reagents & kits enhance performance and usability, solidifying the significant impact on the growth of the overall immunohistochemistry market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall immunohistochemistry (IHC) market:

Among all the regions, North America is expected to dominate the immunohistochemistry (IHC) market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This domination is due to the growing burden of cancer cases in the region, rise in tuberculosis instances, growing product developmental activities, presence of key manufacturers, among others are factors that are expected to fuel the market for immunohistochemistry market in the North America region during the forecast period from 2024 to 2030.

Global Cancer Observatory (2024), estimated that 3.83 million new case of cancer will be diagnosed by 2045 in North American region.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. In tuberculosis, molecular diagnostics enable rapid and accurate identification of mycobacterium tuberculosis, as well as the detection of drug resistance, improving timely diagnosis and treatment.

In cancer, immunohistochemistry helps classify tumors, assess biomarkers like HER2, and guide treatment whereas in tuberculosis, it detects mycobacterial antigens in tissue biopsies, aiding in diagnosis alongside molecular tests. Since cancer instances are rising there is increasing demand for personalized medicine and the adoption of immunohistochemistry in infectious disease diagnostics, such as tuberculosis, further drives the immunohistochemistry market.

Immunohistochemistry enhances precision in both disease detection and treatment selection, ultimately improving patient outcomes. Additionally, the presence of key manufacturers in the region and their strategic business activities will also contribute to the molecular diagnostic market growth.

Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for Immunohistochemistry (IHC). For example, in April 2021, Roche received the US FDA approval for the VENTANA MMR RxDx Panel, the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly).

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American immunohistochemistry market.

Immunohistochemistry (IHC) Market key players:

Some of the key market players operating in the immunohistochemistry (IHC) market include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne, Genemed Biotechnologies, Inc., Abcam plc, BD, Bio SB, Inc., BioGenex, Biocare Medical, LLC, Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories, and others.

Recent Developmental Activities in the Immunohistochemistry (IHC) Market:

• In August 2024, Agilent Technologies Inc., announced that it received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032). It is an immunohistochemistry assay used to detect MAGE-A4 expression in formalin-fixed paraffin-embedded (FFPE) synovial sarcoma tissue.
• In November 2023, Biocare Medical, a leading provider in the immunohistochemistry sector, launched their newest innovation ARC (Antigen Retrieval Chamber).
• In March 2021, Roche launched the DISCOVERY Green HRP kit. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens.

Key Takeaways from the Immunohistochemistry (IHC) Market Report Study

• Market size analysis for current immunohistochemistry (IHC) market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the immunohistochemistry (IHC) market.
• Various opportunities available for the other competitors in the immunohistochemistry (IHC) market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current immunohistochemistry (IHC) market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for immunohistochemistry (IHC) market growth in the coming future?

Target Audience who can be benefited from this immunohistochemistry (IHC) Market Report Study

• Immunohistochemistry (IHC) product providers
• Research organizations and consulting companies
• Immunohistochemistry (IHC)-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in immunohistochemistry (IHC)
• Various end-users who want to know more about the immunohistochemistry (IHC) market and the latest developments in the immunohistochemistry (IHC) market

Frequently Asked Questions for the Immunohistochemistry (IHC) Market:

1. What are immunohistochemistry (IHC)?

• The immunohistochemistry is a technique that uses antibodies to check for certain antigens (markers) in a sample of tissue. The antibodies are usually linked to an enzyme or a fluorescent dye.

2. What is the market for immunohistochemistry (IHC)?

• The immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 3.98 billion by 2030.

3. What are the drivers for the immunohistochemistry (IHC) market?

• The immunohistochemistry (IHC) market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), increasing instances of cancer, rising product developmental activities by market key players, among others that are factors expected to escalate the overall immunohistochemistry (IHC) market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the immunohistochemistry (IHC) market?

• Some of the key market players operating in immunohistochemistry (IHC) include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne, Genemed Biotechnologies, Inc., Abcam plc, BD, Bio SB, Inc., BioGenex, Biocare Medical, LLC, Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories, and others.

5. Which region has the highest share in the immunohistochemistry (IHC) market?

North America is expected to dominate the overall immunohistochemistry market during the forecast period from 2024 to 2030. This domination is due to the growing burden of cancer cases in the region, rise in tuberculosis instances, growing product developmental activities, presence of key manufacturers, among others are factors that are expected to fuel the market for immunohistochemistry market in the North America region during the forecast period from 2024 to 2030.


This product will be delivered within 2 business days.